Treatment of severe hemophilia A without an inhibitor with emicizumab: 128 a case report

Cover Page

Cite item

Full Text

Abstract

   In this article, we report data on the clinical use of emicizumab in a child under 1 year of age with severe hemophilia A without an inhibitor. It was concluded that treatment with emicizumab would be another step toward achieving full control of hemorrhagic syndrome in patients with hemophilia A, especially in children. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.

About the authors

N. N. Andreyeva

Republican Children’s Clinical Hospital of the Ministry of Health of the Udmurt Republic

Author for correspondence.
Email: nataliaizh@yandex.ru
ORCID iD: 0000-0002-1707-2639

Natalia A. Andreeva, Chief External Expert in Pediatric Hematology of the Ministry of Health of the Udmurt Republic, a pediatric oncologist and hematologist at the Outpatient Clinic No. 1 of the Republican Children’s Clinical Hospital of the Ministry of Health of the Udmurt Republic

79 Lenina St., 426009, Izhevsk

Russian Federation

D. N. Korolyova

Republican Children’s Clinical Hospital of the Ministry of Health of the Udmurt Republic

Izhevsk

Russian Federation

E. N. Bogatyryova

Republican Children’s Clinical Hospital of the Ministry of Health of the Udmurt Republic

Izhevsk

Russian Federation

A. A. Sergeyeva

Republican Children’s Clinical Hospital of the Ministry of Health of the Udmurt Republic

Izhevsk

Russian Federation

N. I. Penkina

Izhevsk State Medical Academy of the Ministry of Healthcare of the Russian Federation

Izhevsk

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Andreyeva N.N., Korolyova D.N., Bogatyryova E.N., Sergeyeva A.A., Penkina N.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.